

JULY 6, 1988



St. Vincent Medical Center
UNITED STATES NUCLEAR REGULATORY COMMISSION
REGION III
799 ROOSEVELT ROAD
GLEN ELLYN, ILLINOIS 60137

ATTN: CASSANDRA FRAZIER
MATERIALS LICENSING SECTION

RE: BYPRODUCT MATERIALS LICENSE NO. 34-01216-03
CONTROL NO. 85303
ST. VINCENT MEDICAL CENTER
2213 CHERRY STREET
TOLEDO, OHIO 43608

DEAR MS. FRAZIER:

WITH RESPECT TO AMENDMENT NO. 43 OF THE ABOVE-NOTED BYPRODUCT MATERIALS LICENSE AND YOUR LETTER OF MAY 6, 1988, PLEASE NOTE THE FOLLOWING:

1. ATTACHED PLEASE FIND A LETTER FROM THE CHAIRMAN OF THE RADIATION SAFETY COMMITTEE OF THE MEDICAL COLLEGE OF OHIO, LICENSE NO. 34-13011-04 STATING THEIR AUTHORIZATION FOR ROGER AHUJA, M.D. DR. AHUJA REQUESTED AUTHORIZED USER STATUS FOR MATERIALS IN 10.CFR.35.400 AND 10.CFR.35.600.
2. ATTACHED PLEASE FIND AN ADDITIONAL SUPPLEMENT B FOR SHEILA S. MANION, M.D., DOCUMENTING HER TRAINING AND EXPERIENCE IN THE USE OF IODINE-131 FOR HYPERTHYROIDISM, CARDIAC DYSFUNCTION, AND THYROID CARCINOMA.
3. PLEASE CHANGE ITEM 12H. IN AMENDMENT 43 TO AUTHORIZE M.F. FADELL, M.D. FOR MATERIAL IN 10CFR 35.100 AS WELL AS 35.200 (LISTED TWICE), 35.300, AND 35.500.

AS PER YOUR RECOMMENDATION, I HAVE REFERENCED CONTROL NO. 85303, SINCE THIS INFORMATION REPRESENTS CLARIFICATION OF REQUESTS SUBMITTED FOR AMENDMENT NO. 43. ACCORDINGLY, NO FEE IS ATTACHED TO THIS REQUEST.

THANK YOU IN ADVANCE FOR YOUR ATTENTION TO THESE MATTERS

SINCERELY,

CONTROL NO. 85821

Lawrence O. Leaman
LAWRENCE O. LEAMAN
PRESIDENT
ST. VINCENT MEDICAL CENTER

RECEIVED

JUL 29 1988 JUL 29 1988

REGION III

2213 Cherry Street, Toledo, Ohio 43608-2691 419/321-3232

8905080414 880815
REG3 LIC30
34-01216-03
PNU

88 AUG -3 AM 1:01

RECEIVED

1 FEE NOT REQUIRED

addl - 85303

8/4/88

419-381-4172

419-381-3426

3000 Arlington Avenue
Mailing Address: C.S. 10008
Toledo, Ohio 43699



Medical Physics
419-381-4301

July 7, 1988

Kathryn J. Williford, Ph.D.
St. Vincent Medical Center
2213 Cherry Street
Toledo, OH 43608

Dear Dr. Williford:

In response to your request, I am providing information regarding the activities of Rajender K. Ahuja, M.D. while he was a member of our medical staff. He participated in clinical radiation oncology during the period from June 1982 to December 1986 under our NRC License No. 34-13011-04.

Dr. Ahuja was approved by the Radiation Safety and Radioisotope Committee for the following:

- 1) Use of Byproduct Material Listed in Group VI of 10 CFR 35.100 (Equivalent to current §35.400 sources for brachytherapy)
- 2) Use of iodine-131 as iodide for treatment of thyroid carcinoma
- 3) Use of phosphorus-32 for intracavitary treatment

In support of his application for use of the above materials, he provided evidence of experience and certification by the American Board of Radiation Oncology, June 1982.

Please feel free to contact me if further information is required.

Sincerely,

William J. Potvin, Ph.D., Chairman
Radiation Safety & Radioisotope Committee

WJP/ps

CONTROL NO 85821

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS		KEY TO COLUMN C
FULL NAME		PERSONAL PARTICIPATION SHOULD CONSIST OF:
Sheila S. Manion, M.D.		1-Supervised examination of patients to determine the suitability for radioisotopes, diagnosis and/or treatment and recommendation for prescribed dosage.
STREET ADDRESS		2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
1288 East Meadow		3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.
CITY	STATE	ZIP CODE
Oregon, Ohio		43616

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN


ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION		
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING		
	CARDIAC IMAGING		
	THYROID IMAGING		
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING		
	LUNG IMAGING		
BONE IMAGING			
OTHER			

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	3	
	TREATMENT OF HYPERTHYROIDISM	8	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:		5. PRECEPTOR'S SIGNATURE 	
a. NAME OF SUPERVISOR S.T. Pinsky, M.D.		7. PRECEPTOR'S NAME (Please type or print) S.T. Pinsky, M.D.	
b. NAME OF INSTITUTION St. Vincent Medical Center		8. DATE July 6, 1988	
c. MAILING ADDRESS 2213 Cherry Street			
d. CITY Toledo, Ohio 43608			
5. MATERIALS LICENSE NUMBER(S) 34-01216-03			